SCHEMBL6187008

SCHEMBL6187008

CCNc1cccc(-c2ccc(C=O)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.44
TRIM24 O15164 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
DHODH Q02127 2/20 0.39
CYP17A1 P05093 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
MGLL Q99685 1/20 0.38
ELANE P08246 1/20 0.37
KIF11 P52732 2/20 0.37
ALDH1A1 P00352 2/20 0.37
ALDH3A1 P30838 1/20 0.37
ALDH1A3 P47895 1/20 0.37
LMNA P02545 1/20 0.37
ERN1 O75460 1/20 0.36
PNPLA2 Q96AD5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222132 0.81 DRD1 (0.47) DRD1TRIM24TRIM33CA12CA1
SCHEMBL5538035 0.81 HTR7 (0.45) DRD1TRIM24TRIM33ALDH1A1ALDH3A1
SCHEMBL31023263 0.81 HTR7 (0.45) DRD1TRIM24TRIM33ALDH1A1ALDH3A1
SCHEMBL13996647 0.81 MGLL (0.50) CA2CA9DHODHMGLLLMNA
SCHEMBL24628669 0.80 ERN1 (0.40) DHODHCYP17A1CYP11B1CYP11B2ALDH1A1
SCHEMBL16872445 0.79 CYP3A4 (0.42) DHODHMGLLLMNAMAPTCNR1
SCHEMBL5542224 0.77 MAPT (0.48) ALDH1A1ALDH3A1ALDH1A3LMNAMAPT
SCHEMBL1669178 0.76 DRD1 (0.59) DRD1TRIM24TRIM33CA12CA1
SCHEMBL6792137 0.76 CYP17A1 (0.60) CYP17A1CYP11B1CYP11B2MGLLALDH1A1
SCHEMBL13485211 0.76 KIF11 (0.62) KIF11ALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD DRD1 2414/4885TRIM24 3617/4885TRIM33 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.